Literature DB >> 15022339

Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population.

Eswar Krishnan1, Tuulikki Sokka, Arja Häkkinen, Helen Hubert, Pekka Hannonen.   

Abstract

OBJECTIVE: The Health Assessment Questionnaire (HAQ) disability index (DI) has been commonly used in rheumatology to quantify functional disability in patient groups, but current general population values of this index are not available. This study was undertaken to establish normative values for the HAQ DI in a general population and to analyze its correlates.
METHODS: The HAQ DI (range of scores 0-3) was measured in a random sample of 1,530 adults in the Central Finland District. Prevalence rates of disability by strata of age, sex, education level, body mass index (BMI), and health behaviors (including smoking and exercise habits) were calculated. Pearson's product-moment correlation coefficient and ordinary least squares regression were used to analyze the data.
RESULTS: The estimated population mean HAQ DI was 0.25 (95% confidence interval 0.22-0.28), and 32% of respondents had at least some disability. Both for men and for women, functional disability increased exponentially with age. The HAQ DI was correlated with pain (r = 0.58) and global self assessment (r = 0.61). The prevalence of disability decreased with increasing number of years of education, lower BMI, and increasing frequency of physical exercise.
CONCLUSION: Almost one-third of the general population has some functional disability. Functional disability is associated in part with lifestyle choices and increases with age in a nonlinear manner. The normative values of the HAQ DI that we have presented could be used as a reference benchmark for clinical and epidemiologic studies using this measure of disability.

Entities:  

Mesh:

Year:  2004        PMID: 15022339     DOI: 10.1002/art.20048

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  66 in total

1.  Late-age onset systemic sclerosis.

Authors:  Rebecca L Manno; Fredrick M Wigley; Allan C Gelber; Laura K Hummers
Journal:  J Rheumatol       Date:  2011-06-17       Impact factor: 4.666

2.  Population-based normative values for the Western Ontario and McMaster (WOMAC) osteoarthritis index and the Australian/Canadian (AUSCAN) hand osteoarthritis index functional subscales.

Authors:  Nicholas Bellamy; C Wilson; J Hendrikz
Journal:  Inflammopharmacology       Date:  2009-12-19       Impact factor: 4.473

3.  Evaluation of functional capacity in individuals with signs and symptoms of musculoskeletal disease: results of the BRAZCO population study (Brazilian COPCORD Study).

Authors:  Fabio Jennings; Emilia Inoue Sato; Geraldo da Rocha Castelar Pinheiro; Marcos Bosi Ferraz
Journal:  Rheumatol Int       Date:  2015-06-09       Impact factor: 2.631

4.  Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS(®) Physical Function.

Authors:  Benjamin D Schalet; Dennis A Revicki; Karon F Cook; Eswar Krishnan; Jim F Fries; David Cella
Journal:  J Gen Intern Med       Date:  2015-10       Impact factor: 5.128

5.  Musculoskeletal Pain, Self-reported Physical Function, and Quality of Life in the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) Cohort.

Authors:  Sharon Bout-Tabaku; Marc P Michalsky; Todd M Jenkins; Amy Baughcum; Meg H Zeller; Mary L Brandt; Anita Courcoulas; Ralph Buncher; Michael Helmrath; Carroll M Harmon; Mike K Chen; Thomas H Inge
Journal:  JAMA Pediatr       Date:  2015-06       Impact factor: 16.193

6.  Validity of adopting a Health Assessment Questionnaire Disability Index less than 0.5 as a target in elderly rheumatoid arthritis patients.

Authors:  Ichiro Yoshii; Tatsumi Chijiwa; Naoya Sawada
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

7.  Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

Authors:  D van der Heijde; L Klareskog; A Singh; J Tornero; J Melo-Gomes; C Codreanu; R Pedersen; B Freundlich; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

8.  Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Authors:  Michael H Schiff; Elaine B Yu; Michael E Weinblatt; Larry W Moreland; Mark C Genovese; Barbara White; Amitabh Singh; Yun Chon; J Michael Woolley
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

9.  Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.

Authors:  B Combe; C Codreanu; U Fiocco; M Gaubitz; P P Geusens; T K Kvien; K Pavelka; P N Sambrook; J S Smolen; R Khandker; A Singh; J Wajdula; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2008-09-15       Impact factor: 19.103

10.  Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study.

Authors:  Tuulikki Sokka; Sergio Toloza; Maurizio Cutolo; Hannu Kautiainen; Heidi Makinen; Feride Gogus; Vlado Skakic; Humeira Badsha; Tõnu Peets; Asta Baranauskaite; Pál Géher; Ilona Ujfalussy; Fotini N Skopouli; Maria Mavrommati; Rieke Alten; Christof Pohl; Jean Sibilia; Andrea Stancati; Fausto Salaffi; Wojciech Romanowski; Danuta Zarowny-Wierzbinska; Dan Henrohn; Barry Bresnihan; Patricia Minnock; Lene Surland Knudsen; Johannes Wg Jacobs; Jaime Calvo-Alen; Juris Lazovskis; Geraldo da Rocha Castelar Pinheiro; Dmitry Karateev; Daina Andersone; Sylejman Rexhepi; Yusuf Yazici; Theodore Pincus
Journal:  Arthritis Res Ther       Date:  2009-01-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.